CMV INFECTION
Clinical trials for CMV INFECTION explained in plain language.
Never miss a new study
Get alerted when new CMV INFECTION trials appear
Sign up with your email to follow new studies for CMV INFECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Transplant drug tweak may tame common virus
Disease control Not yet recruitingThis study tests whether adjusting the dose of anti-rejection drugs can help control CMV infection in organ transplant recipients. About 100 adults who have had a kidney, liver, heart, lung, or pancreas transplant and now have a CMV infection will take part. Researchers will moni…
Matched conditions: CMV INFECTION
Phase: PHASE4 • Sponsor: Oriol Manuel • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New trial aims to stop CMV eye inflammation from returning
Disease control Not yet recruitingThis study tests whether oral valganciclovir or ganciclovir eye drops can reduce the virus causing eye inflammation and prevent flare-ups. About 117 adults with CMV anterior uveitis will receive either antiviral treatment or placebo for 7 days, then some continue for 12 months. T…
Matched conditions: CMV INFECTION
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New scoring system could cut Post-Transplant infections
Disease control Not yet recruitingThis study tests a scoring system that uses immune system recovery to decide how long patients should take antiviral medicine after a stem cell transplant. The goal is to prevent a common virus called CMV from causing infection. About 1,114 transplant recipients will take part to…
Matched conditions: CMV INFECTION
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug may offer safer CMV prevention for kidney transplant patients
Prevention Not yet recruitingThis study tests if letermovir works as well as valganciclovir in preventing CMV infection in 300 kidney transplant patients who are CMV-positive. Both drugs are given for 90 days after transplant. Researchers will also check if letermovir is easier to tolerate and how long it ta…
Matched conditions: CMV INFECTION
Phase: PHASE4 • Sponsor: Elisabeth Kincaide • Aim: Prevention
Last updated Jun 27, 2026 12:30 UTC